CLAIMS

1. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 and at least one of a pharmaceutically acceptable salt, sugar, sugar alcohol, non-ionic surfactant, and buffering agent in the manufacture of a medicament for the treatment of inherited thrombotic thrombocytopenic purpura (TTP) in a mammal in need thereof by subcutaneous administration, wherein the therapeutically effective amount of ADAMTS13 comprises 20-4000 activity units per kilogram.

2. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 and at least one of a pharmaceutically acceptable salt, sugar, sugar alcohol, non-ionic surfactant, and buffering agent in the manufacture of a medicament for the treatment of acquired thrombotic thrombocytopenic purpura (TTP) in a mammal in need thereof by subcutaneous administration, wherein the therapeutically effective amount of ADAMTS13 comprises 20-4000 activity units per kilogram.

3. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 and at least one of a pharmaceutically acceptable salt, sugar, sugar alcohol, non-ionic surfactant, and buffering agent in the manufacture of a medicament for the treatment of cerebral infarction in a mammal in need thereof by subcutaneous administration, wherein the therapeutically effective amount of ADAMTS13 comprises 20-4000 activity units per kilogram.

4. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 and at least one of a pharmaceutically acceptable salt, sugar, sugar alcohol, non-ionic surfactant, and buffering agent in the manufacture of a medicament for the treatment of myocardial infarction in a mammal in need thereof by subcutaneous administration, wherein the therapeutically effective amount of ADAMTS13 comprises 20-4000 activity units per kilogram.

5. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 and at least one of a pharmaceutically acceptable salt, sugar, sugar alcohol, non-ionic surfactant, and buffering agent in the manufacture of a medicament for the treatment of ischemic reperfusion injury in a mammal in need thereof by subcutaneous

administration, wherein the therapeutically effective amount of ADAMTS13 comprises 20-4000 activity units per kilogram.

6. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 and at least one of a pharmaceutically acceptable salt, sugar, sugar alcohol, non-ionic surfactant, and buffering agent in the manufacture of a medicament for the treatment of deep vein thrombosis in a mammal in need thereof by subcutaneous administration, wherein the therapeutically effective amount of ADAMTS13 comprises 20-4000 activity units per kilogram.

7. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 and at least one of a pharmaceutically acceptable salt, sugar, sugar alcohol, non-ionic surfactant, and buffering agent in the manufacture of a medicament for the treatment of treating sepsis-related disseminated intravascular coagulation in a mammal in need thereof by subcutaneous administration, wherein the therapeutically effective amount of ADAMTS13 comprises 20-4000 activity units per kilogram.

8. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 and at least one of a pharmaceutically acceptable salt, sugar, sugar alcohol, non-ionic surfactant, and buffering agent in the manufacture of a medicament for the treatment of inherited thrombotic thrombocytopenic purpura (TTP) in a mammal in need thereof by subcutaneous administration, wherein the therapeutically effective amount of ADAMTS13 comprises at least 120-300% of the amount of a standard intravenous dose for ~~a specific indication~~inherited TTP as measured in activity units per kilogram.

9. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 and at least one of a pharmaceutically acceptable salt, sugar, sugar alcohol, non-ionic surfactant, and buffering agent in the manufacture of a medicament for the treatment of acquired thrombotic thrombocytopenic purpura (TTP) in a mammal in need thereof by subcutaneous administration, wherein the therapeutically effective amount of ADAMTS13 comprises at least 120-300% of the amount of a standard intravenous dose for ~~a specific indication~~acquired TTP as measured in activity units per kilogram.

10. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 and at least one of a pharmaceutically acceptable salt, sugar, sugar alcohol, non-ionic surfactant, and buffering agent in the manufacture of a medicament for the treatment of cerebral infarction in a mammal in need thereof by subcutaneous administration, wherein the therapeutically effective amount of ADAMTS13 comprises at least 120-300% of the amount of a standard intravenous dose for ~~a specific indication~~cerebral infarction as measured in activity units per kilogram.

11. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 and at least one of a pharmaceutically acceptable salt, sugar, sugar alcohol, non-ionic surfactant, and buffering agent in the manufacture of a medicament for the treatment of myocardial infarction in a mammal in need thereof by subcutaneous administration, wherein the therapeutically effective amount of ADAMTS13 comprises at least 120-300% of the amount of a standard intravenous dose for ~~a specific indication~~myocardial infarction as measured in activity units per kilogram.

12. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 and at least one of a pharmaceutically acceptable salt, sugar, sugar alcohol, non-ionic surfactant, and buffering agent in the manufacture of a medicament for the treatment of ischemic reperfusion injury in a mammal in need thereof by subcutaneous administration, wherein the therapeutically effective amount of ADAMTS13 comprises at least 120-300% of the amount of a standard intravenous dose for ~~a specific indication~~ischemic reperfusion injury as measured in activity units per kilogram.

13. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 and at least one of a pharmaceutically acceptable salt, sugar, sugar alcohol, non-ionic surfactant, and buffering agent in the manufacture of a medicament for the treatment of deep vein thrombosis in a mammal in need thereof by subcutaneous administration, wherein the therapeutically effective amount of ADAMTS13 comprises at least 120-300% of the amount of a standard intravenous dose for ~~a specific indication~~deep vein thrombosis as measured in activity units per kilogram.

14. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 and at least one of a pharmaceutically acceptable salt, sugar, sugar alcohol, non-ionic surfactant, and buffering agent in the manufacture of a medicament for the treatment of sepsis-related disseminated intravascular coagulation in a mammal in need thereof by subcutaneous administration, wherein the therapeutically effective amount of ADAMTS13 comprises at least 120-300% of the amount of a standard intravenous dose for sepsis-related disseminated intravascular coagulation ~~a specific indication~~ as measured in activity units per kilogram.

15. The use of claim 8, wherein the specific indication is inherited TTP and the standard intravenous dose is 10-80 activity units per kilogram.

16. The use of claim 9, wherein the specific indication is acquired TTP and the standard intravenous dose is 20-1000 activity units per kilogram.

17. The use of claim 11 or 12, wherein the specific indication is myocardial infarction and/or ischemic reperfusion injury and the standard intravenous dose is 20-2000 activity units per kilogram.

18. The use of claim 10 or 12, wherein the specific indication is cerebral infarction and/or ischemic reperfusion injury and the standard intravenous dose is 20-2000 activity units per kilogram.

19. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 in the manufacture of a medicament for the treatment of acute inflammation, chronic inflammation, *plasmodium falciparum* malaria, snake bites, frostbite, burns, hemolytic uremic syndrome, arterial thrombosis, coronary heart disease, or atherosclerosis in a mammal in need thereof by subcutaneous administration.

20. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 in the manufacture of a medicament for reducing a neurological manifestation and/or reducing fatigue associated with thrombotic thrombocytopenic purpura (TTP) in a mammal in need thereof by subcutaneous administration.

21. The use of claim 20, wherein the neurological manifestation is an alteration of mental status, stroke, seizures, hemiplegia, paresthesias, visual disturbance, and/or aphasia.

22. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 in the manufacture of a medicament for treating thrombotic thrombocytopenic purpura (TTP), cerebral infarction, myocardial infarction. ischemic/reperfusion injury, deep vein thrombosis, or sepsis-related disseminated intravascular coagulation in a mammal in need thereof by subcutaneous administration.

23. The use of any one of claims 20-22, wherein the TTP is inherited TTP.

24. The use of any one of claims 20-22, wherein the TTP is acquired TTP.

25. The use of any one of claims 1-24, wherein the bioavailability of the ADAMTS13 after subcutaneous administration is 50-80% as compared to intravenous administration normalized for the same dose.

26. The use of any one of claims 1-25, wherein the bioavailability of the ADAMTS13 after subcutaneous administration is at least 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, or at least about 80% as compared to intravenous administration normalized for the same dose.

27. The use of any one of claims 1-26, wherein the therapeutically effective amount comprises at least 20-100 activity units per kilogram.

28. The use of any one of claims 1-26, wherein the therapeutically effective amount comprises at least 20-160 activity units per kilogram.

29. The use of any one of claims 1-26, wherein the therapeutically effective amount comprises at least 20-2000 activity units per kilogram.

30. The use of any one of claims 1-26, wherein the therapeutically effective amount comprises at least 20-4000 activity units per kilogram.

31. The use of any one of claims 1-26, wherein the therapeutically effective amount comprises at least 40-2000 activity units per kilogram.

32. The use of any one of claims 1-26, wherein the therapeutically effective amount comprises at least 40-4000 activity units per kilogram.

33. The use of any one of claims 1-32, wherein the ADAMTS13 is to be administered in a single bolus injection, monthly, every two weeks, weekly, twice a week, daily, every 12 hours, every 8 hours, every six hours, every four hours, or every two hours.

34. The use of any one of claims 1-33, wherein the ADAMTS13 is recombinant.

35. The use of any one of claims 1-33, wherein the ADAMTS13 is plasma derived.

36. The use of any one of claims 1-35, wherein the mammal is a human.

37. The use of any one of claims 1-36, wherein the composition is a stable aqueous solution ready for administration.

38. The use of any one of claims 1-37, wherein the composition is lyophilized.

39. The use of any one of claims 1-38, wherein the composition is reconstituted with a pharmaceutically acceptable vehicle suitable for injection prior to administration.